MTOR and hepatocellular carcinoma: Further analysis of the survival outcomes of HCC patients revealed that patients with relatively higher KIF18B or p-mTOR expression had poorer overall survival and disease-free survival than those with relatively lower KIF18B or p-mTOR expression (Fig. 1I, J).